Chief Medical Officer
Portal Therapeutics, Inc. · OncoZenge AB · FluoGuide A/S
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chief Medical Officer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:50 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT07820085 · A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)Portal Therapeutics, Inc. · recruiting · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2 · study director
- Ph3NCT07672236 · A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.OncoZenge AB · recruiting · Head & Neck Cancer, Oral Mucositis · study director
- Ph2NCT07609472 · FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade GliomaFluoGuide A/S · not yet recruiting · High-Grade Glioma (WHO III-IV) · study director
- Ph2NCT07511972 · Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, Inc · withdrawn · CRC · study director
- Ph2NCT07287189 · Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc. · active not recruiting · Duchenne Muscular Dystrophy, Duchenne, DMD · study director
- Ph1NCT07284186 · First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsPlexium, Inc. · recruiting · Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma · study director
- Ph1NCT07264270 · Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral RadiculopathyConsano Bio · recruiting · Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain · study director
- Ph1NCT07205926 · First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young AdultsInventprise Inc. · recruiting · Shigella, Diarrhea · study director
- Ph1NCT07146191 · RE104 Radiolabeled Mass Balance (hAME) StudyReunion Neuroscience Inc · completed · Healthy Participant Study · study director
- Ph2NCT07089043 · A Study in Subjects With Neurogenic Orthostatic HypotensionCuraSen Therapeutics, Inc. · active not recruiting · Neurogenic Orthostatic Hypotension · study director
- Ph2NCT07002034 · RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesReunion Neuroscience Inc · recruiting · Adjustment Disorder · study director
- Ph2NCT06971900 · GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic ProtoporphyriaPortal Therapeutics, Inc. · completed · Erythropoietic Protoporphyria (EPP) · study director
- Ph1NCT06950034 · A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)Solu Therapeutics, Inc · recruiting · Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1 · study director
- Ph3NCT06917404 · A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.Paradigm Biopharmaceuticals Ltd. · active not recruiting · Osteoarthritis, Knee · study director
- Ph1NCT06914869 · Drug-Drug Interaction Potential of MavorixaforX4 Pharmaceuticals · completed · Healthy Participants · study director
- Ph2/Ph3NCT06892288 · A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGGlycomine, Inc. · active not recruiting · Phosphomannomutase 2 Deficiency, PMM2-CDG · study director
- N/ANCT06882317 · Long Term Follow-up Study for Subjects Administered CLBR001Calibr, a division of Scripps Research · enrolling by invitation · Long Term Follow-Up · study director
- Ph1NCT06878248 · A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerCalibr, a division of Scripps Research · terminated · Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast · study director
- Ph1/Ph2NCT06874621 · VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseVoyager Therapeutics · active not recruiting · Alzheimer's Disease (AD) · study director
- Ph2NCT06865079 · 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the KneeOrthoTrophix, Inc · active not recruiting · Osteoarthritis (OA) of the Knee · study chair
- Ph1NCT06858696 · A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionX4 Pharmaceuticals · completed · Hepatic Insufficiency · study director
- Ph2NCT06850727 · Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisOdyssey Therapeutics, Inc. · recruiting · Ulcerative Colitis (UC), UC - Ulcerative Colitis · study director
- Ph1NCT06732180 · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's DiseaseGain Therapeutics, Inc. · recruiting · Parkinson Disease · study director
- Ph2NCT06728553 · Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in AdultsManistee Therapeutics · completed · Migraine · study director
- Ph2NCT06657859 · Open-Label Extension Study to Assess GLM101 in PMM2-CDG PatientsGlycomine, Inc. · enrolling by invitation · Pmm2-CDG, Phosphomannomutase 2 Deficiency · study director
- Ph1NCT06659263 · RE104 Clinical Lactation StudyReunion Neuroscience Inc · completed · Lactation · study director
- Ph2NCT06605651 · Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.Phagenix · not yet recruiting · Hip Prosthesis Infection, Knee Prosthesis Infection · study director
- Ph1NCT06589219 · Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary FibrosisCalibr, a division of Scripps Research · completed · Pulmonary Fibroses, Idiopathic · principal investigator
- Ph1/Ph2NCT06384807 · A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsBiohaven Therapeutics Ltd. · recruiting · Solid Tumor · study director
- Ph2NCT06374797 · A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"CalciMedica, Inc. · terminated · Acute Kidney Injury · study director
- Ph1NCT06346509 · Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult ParticipantsPortal Therapeutics, Inc. · completed · Healthy Adult Participants · study director
- Ph2NCT05865041 · Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata ParticipantsASLAN Pharmaceuticals · unknown · Alopecia Areata · study director
- Ph1/Ph2NCT05822908 · A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HDVico Therapeutics B. V. · recruiting · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease · study director
- Ph2NCT05694884 · Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With DupilumabASLAN Pharmaceuticals · unknown · Atopic Dermatitis · study director
- Ph1NCT05692570 · A Study of PBI-200 With Ritonavir or Cobicistat in Healthy VolunteersPyramid Biosciences · completed · Drug-drug Interaction · study director
- Ph1NCT05690932 · A Formulation Bridging and Food Effect Study of PBI-200 in Healthy VolunteersPyramid Biosciences · completed · Formulation Bridging, Food Effect · study director
- Ph1NCT05542355 · EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's DiseaseExeliom Biosciences · terminated · Crohn Disease · study director
- Ph1NCT05514353 · A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical CreamPyramid Biosciences · completed · Healthy Volunteers, Psoriasis · study director
- Ph2NCT05414422 · A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRDPerception Neuroscience · completed · Treatment Resistant Depression · study director
- Ph1NCT05403554 · A Study of NI-1801 in Patients with Mesothelin Expressing Solid CancersLight Chain Bioscience - Novimmune SA · unknown · Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer · study director
- Ph2NCT05309200 · A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney InjuryOcelot Bio, Inc · completed · Cirrhosis, Ascites, Hepatorenal Syndrome · study chair
- Ph1NCT05270213 · Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsRiboscience, LLC. · recruiting · Advanced Cancer · study director
- Ph1NCT05238337 · A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200Pyramid Biosciences · completed · Absorption, Metabolism and Excretion in Healthy Volunteers · study director
- Ph1/Ph2NCT05181462 · Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.Cantargia AB · completed · Triple Negative Breast Cancer · study director
- Ph2/Ph3NCT05176717 · Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)Laboratoires Thea · terminated · Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind · study director
- Ph1NCT05160389 · A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200Pyramid Biosciences · completed · Food Effect in Healthy Volunteers · study director
- Ph2NCT05158023 · Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic DermatitisASLAN Pharmaceuticals · completed · Atopic Dermatitis · study director
- Ph2NCT05104463 · A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's DiseaseCuraSen Therapeutics, Inc. · completed · Mild Cognitive Impairment, Dementia · study director
- Ph3NCT05082584 · Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsAkebia Therapeutics · withdrawn · Anemia of Chronic Kidney Disease · study director
- Ph3NCT05082571 · Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseAkebia Therapeutics · withdrawn · Anemia of Chronic Kidney Disease · study director
- Ph1NCT05033912 · A Study of CST-2032 in Subjects With Cognitive ImpairmentCuraSen Therapeutics, Inc. · withdrawn · Mild Cognitive Impairment (MCI), Parkinson Disease (PD) · study director
- Ph2NCT05034874 · Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200InterveXion Therapeutics, LLC · terminated · Methamphetamine-dependence, Methamphetamine Abuse · study director
- Ph1NCT05027451 · Safety, Tolerability, and Pharmacokinetics of IXT-m200InterveXion Therapeutics, LLC · completed · Healthy · study director
- N/ANCT05017662 · A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072Ariceum Therapeutics GmbH · completed · Neuroendocrine Tumors · study director
- Ph2NCT04977024 · SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerGeoVax, Inc. · active not recruiting · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia · principal investigator
- Ph2NCT04935762 · A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)CuraSen Therapeutics, Inc. · withdrawn · Freezing of Gait Symptoms in Parkinson's Disease · study director
- N/ANCT04926376 · Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)ABK Biomedical · completed · Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer · study director
- Ph1/Ph2NCT04913337 · Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, Inc · unknown · Mesothelioma, Glioblastoma, Renal Cell Carcinoma · study director
- Ph1NCT04901806 · Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid TumorsPyramid Biosciences · terminated · Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor · study director
- Ph1NCT04882631 · A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy ParticipantsPyramid Biosciences · completed · Healthy Volunteers · study director
- Ph2NCT04866563 · A Study of Efficacy and Safety of AX-8 in Chronic CoughAxalbion SA · completed · Chronic Cough · study director
- Ph3NCT04810962 · Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-studyFormosa Pharmaceuticals, Inc. · completed · Ocular Inflammation and Pain After Cataract Surgery · study director
- Ph1/Ph2NCT04747431 · A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 GenesPassage Bio, Inc. · terminated · Frontotemporal Dementia, FTD, FTD-GRN · study chair
- Ph2NCT04739423 · A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative DisordersCuraSen Therapeutics, Inc. · completed · Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia · study director
- Ph2NCT04715230 · Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine OverdoseInterveXion Therapeutics, LLC · terminated · Methamphetamine Intoxication (Disorder) · study director
- Ph2NCT04707573 · Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4Akebia Therapeutics · completed · Chronic Kidney Disease · study director
- Ph3NCT04707768 · Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsAkebia Therapeutics · completed · Anemia Associated With Chronic Kidney Disease (CKD) · study director
- Ph3NCT04649411 · Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney DiseaseKeryx Biopharmaceuticals · withdrawn · Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease · study director
- Ph1/Ph2NCT04639466 · A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 InfectionGeoVax, Inc. · completed · COVID-19 Infection · principal investigator
- Early Ph1NCT04630353 · A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical CancerAstraZeneca · terminated · HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer · study director
- Ph1NCT04561245 · ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityAltimmune, Inc. · completed · Obesity, Nonalcoholic Steatohepatitis · study director
- Ph3NCT04523727 · Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney DiseaseKeryx Biopharmaceuticals · suspended · Hyperphosphatemia Related to Chronic Kidney Disease · study director
- Ph1NCT04468347 · Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's DiseaseAvid Radiopharmaceuticals · completed · Alzheimer Disease, Mild Cognitive Impairment · study director
- Ph3NCT04400331 · Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseNeurocrine Biosciences · terminated · Chorea, Huntington · study director
- Ph1NCT04386304 · Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyEpirium Bio Inc. · completed · Becker Muscular Dystrophy · study director
- Ph3
- Ph3NCT04102579 · Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseNeurocrine Biosciences · completed · Chorea, Huntington · study director
- Ph2NCT04089735 · A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract SurgeryFormosa Pharmaceuticals, Inc. · completed · Ocular Inflammation and Pain After Cataract Surgery · study director
- Ph2NCT04085341 · A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein OcclusionGraybug Vision · completed · Diabetic Macular Edema, Retina Vein Occlusion · study director
- Ph3NCT03995108 · Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeX4 Pharmaceuticals · completed · WHIM Syndrome · study director
- Ph1NCT03955666 · A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy SubjectsProvention Bio, Inc. · completed · Safety · study director
- Ph2NCT03953079 · A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDGraybug Vision · completed · Neovascular Age-Related Macular Degeneration · study director
- Ph1/Ph2NCT03913130 · Extension Study to Study PQ-110-001 (NCT03140969)Laboratoires Thea · terminated · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis · study director
- Ph4NCT03891862 · Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaNeurocrine Biosciences · completed · Tardive Dyskinesia (TD) · study director
- Ph3NCT03875729 · Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabProvention Bio, Inc. · completed · Type 1 Diabetes Mellitus · study director
- Ph1/Ph2NCT03846193 · FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMDGyroscope Therapeutics Limited · terminated · Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease · study director
- Ph1NCT03809052 · A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy SubjectsGalecto Biotech AB · completed · Safety and Tolerability · study chair
- Ph2NCT03799627 · Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaAkebia Therapeutics · completed · Anemia, Dialysis-dependent Chronic Kidney Disease · study director
- Ph1NCT03737448 · TRimetazidine for acUte on Chronic Liver Failure STudyMartin Pharmaceuticals · suspended · Acute-On-Chronic Liver Failure · study director
- Ph3NCT03703882 · Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyCatabasis Pharmaceuticals · completed · Muscular Dystrophy, Duchenne · study chair
- Ph4NCT03698331 · The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineNeurocrine Biosciences · completed · Tardive Dyskinesia (TD) · study director
- Ph2NCT03687242 · Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaSpruce Biosciences · completed · Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency · study director
- Ph2NCT03629080 · A Study of CMV Vaccine (HB-101) in Kidney Transplant PatientsHookipa Biotech GmbH · completed · Cytomegalovirus (CMV) Infection, Kidney Transplantation · study director
- Ph1NCT03570918 · MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyMacroGenics · completed · HIV-1-infection · study director
- Ph3NCT03567057 · A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentAdamas Pharmaceuticals, Inc. · completed · Multiple Sclerosis, Walking Impairment · study director
- Ph1NCT03496870 · A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Neurocrine Biosciences · completed · Parkinson Disease · study director
- Ph2NCT03467477 · Tau Screening Study in Subjects With Early Symptomatic ADAvid Radiopharmaceuticals · completed · Alzheimer Disease · study chair
- Ph2NCT03322462 · Tau Screening Study in Patients With Early Symptomatic ADAvid Radiopharmaceuticals · completed · Alzheimer Disease · study chair
- Ph2NCT03257462 · Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaSpruce Biosciences · completed · Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia · study director
- Ph3NCT03199963 · Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast TissueBHR Pharma, LLC · terminated · Mammographic Breast Density · study director
- N/ANCT03173300 · Natural History Study Protocol in PMM2-CDG (CDG-Ia)Glycomine, Inc. · completed · Phosphomannomutase 2 Deficiency · study director
- Ph1/Ph2NCT03140969 · Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneLaboratoires Thea · completed · Leber's Congenital Amaurosis · study director
- Ph1NCT03040713 · Flortaucipir PET Imaging in Subjects With FTDAvid Radiopharmaceuticals · completed · Frontotemporal Dementia · study chair
- Ph3NCT03032510 · Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract InfectionsTetraphase Pharmaceuticals, Inc · completed · Complicated Urinary Tract Infections · study director
- Ph1NCT02982941 · Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsMacroGenics · completed · Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma · study director
- Ph1/Ph2NCT02936323 · PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersTarveda Therapeutics · completed · Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma · study director
- Ph1/Ph2NCT02923531 · Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaX4 Pharmaceuticals · terminated · Clear Cell Renal Cell Carcinoma · study director
- N/ANCT02918539 · Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsAvid Radiopharmaceuticals · completed · Alzheimer Disease, Cognition Disorders · study chair
- Ph3NCT02892149 · Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)Akebia Therapeutics · completed · Anemia, Dialysis-Dependent Chronic Kidney Disease · study director
- Ph3NCT02865850 · Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)Akebia Therapeutics · completed · Anemia, Dialysis-Dependent Chronic Kidney Disease · study director
- Ph3NCT02784704 · Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal InfectionsTetraphase Pharmaceuticals, Inc · completed · Complicated Intra-abdominal Infections, Complicated Appendicitis · study director
- Ph3NCT02680574 · Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)Akebia Therapeutics · completed · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease · study director
- Ph3NCT02648347 · Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseAkebia Therapeutics · completed · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease · study director
- Ph3NCT02516046 · 18F-AV-1451 Autopsy StudyAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study chair
- Ph1NCT02512029 · 18F-AV-1451 PET Imaging in TBIAvid Radiopharmaceuticals · withdrawn · Traumatic Brain Injury · study chair
- Ph1NCT02381314 · Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerMacroGenics · completed · Melanoma, Non Small Cell Lung Cancer · study director
- Ph1NCT02376036 · Phase 1 Study of MGD010 in Healthy SubjectsMacroGenics · completed · Healthy Subjects · study director
- Ph2NCT02260193 · 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisAkebia Therapeutics · completed · Anemia, End Stage Renal Disease · study director
- Ph1NCT02120664 · Florbetapir Calibration to the Centiloid ScaleAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study chair
- Ph4NCT02107599 · The Feasibility of Florbetapir Quantitation in EuropeAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph2NCT02079766 · 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic EncephalopathyAvid Radiopharmaceuticals · completed · Chronic Traumatic Encephalopathy · study chair
- Ph2NCT02051764 · Imaging Characteristics of a Follow-up 18F-AV-1451 ScanAvid Radiopharmaceuticals · terminated · Alzheimer's Disease · study chair
- Ph4NCT02051790 · Evaluation of Reader Training ProcessesAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph1NCT01992380 · A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired SubjectsAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study chair
- Ph4NCT01946243 · The Feasibility of Florbetapir QuantitationAvid Radiopharmaceuticals · completed · Alzheimers Disease · study director
- Ph1NCT01918930 · Tissue Procurement Substudy for Participants in Study CP-MGA271-01MacroGenics · terminated · Melanoma · study director
- Ph2NCT01906489 · 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaAkebia Therapeutics · completed · Anemia, Chronic Kidney Disease · study director
- Ph2NCT01890343 · Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.Avid Radiopharmaceuticals · completed · Alzheimer's Disease, Frontotemporal Dementia · study director
- Ph3NCT01876849 · An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Early Ph1NCT01733355 · A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807Avid Radiopharmaceuticals · terminated · Alzheimers Disease, AD · study director
- Early Ph1NCT01723488 · A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808Avid Radiopharmaceuticals · terminated · Alzheimers Disease · study director
- Ph1NCT01710371 · Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy ControlsAvid Radiopharmaceuticals · completed · Type 2 Diabetes · study director
- Ph4NCT01703702 · Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclineAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph2/Ph3NCT01662882 · A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)Avid Radiopharmaceuticals · completed · Alzheimer's Disease, Mild Cognitive Impairment · study director
- Ph1NCT01660815 · A Study of Florbetapir (18F) in Japanese Healthy VolunteersAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph1NCT01564706 · A Study of 18F-AV-45 in Healthy VolunteersAvid Radiopharmaceuticals · completed · Alzheimer Disease · study director
- Ph3NCT01565382 · Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)Avid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Early Ph1NCT01565291 · A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly VolunteersAvid Radiopharmaceuticals · completed · Alzheimer Disease · study director
- N/ANCT01565356 · Evaluation of PET Scan Timing Relative to AV-45 Injection TimeAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph1NCT01565330 · A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy VolunteersAvid Radiopharmaceuticals · completed · Alzheimer Disease · study director
- Ph1NCT01565343 · A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy VolunteersAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- N/ANCT01565369 · Evaluation of Physician Training Methods to Read Florbetapir-PET ScansAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph2/Ph3NCT01550484 · A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersAvid Radiopharmaceuticals · completed · Parkinson's Disease, Primary Parkinsonism, Lewy Body Parkinson's Disease · study director
- N/ANCT01550549 · Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET ScansAvid Radiopharmaceuticals · completed · Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases · study director
- Ph1NCT01544881 · Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 DiabetesMannkind Corporation · completed · Type 1 Diabetes Mellitus · study chair
- Ph2NCT01518374 · Clinical Evaluation of Florbetapir F 18 (18F-AV-45)Avid Radiopharmaceuticals · completed · Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases · study director
- Ph1NCT01515384 · A Trial of 18F-AV-133 Positron Emission Tomography (PET)Avid Radiopharmaceuticals · terminated · Type 1 Diabetes, Type 2 Diabetes · study director
- Ph1/Ph2NCT01503944 · A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)Avid Radiopharmaceuticals · completed · Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease · study director
- Ph1NCT01490762 · Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C InhalerMannkind Corporation · completed · Healthy · study chair
- Ph3NCT01400425 · Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive DeclineAvid Radiopharmaceuticals · completed · Progressive Cognitive Decline · study director
- Ph1NCT01391143 · Safety Study of MGA271 in Refractory CancerMacroGenics · completed · Prostate Cancer, Melanoma, Renal Cell Carcinoma · study director
- Ph2NCT01381094 · 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaAkebia Therapeutics · completed · Anemia, Kidney Disease · study director
- Ph2NCT01235936 · Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaAkebia Therapeutics · completed · Anemia, Kidney Disease · study director
- Ph1NCT01228760 · A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate CancerAstellas Pharma Inc · completed · Prostate Neoplasms · study director
- Ph1NCT01114230 · A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney CancerAstellas Pharma Inc · completed · Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F · study director
- Ph3NCT01029886 · Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01003184 · Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00989261 · Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)Daiichi Sankyo · completed · Acute Myeloid Leukemia · study director
- Ph3NCT00960661 · A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00935532 · Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00917267 · A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian SubjectsAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00902291 · A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic CancerAstellas Pharma Inc · completed · Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease · study director
- Ph4NCT00870194 · A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00857532 · Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsAvid Radiopharmaceuticals · completed · Parkinson's Disease · study director
- Ph3NCT00857415 · Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the BrainAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph2NCT00857506 · Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)Avid Radiopharmaceuticals · completed · Alzheimer's Disease, Mild Cognitive Impairment · study director
- Ph2NCT00855868 · Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal IndividualsAvid Radiopharmaceuticals · completed · Alzheimer's Disease · study director
- Ph3NCT00844662 · Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer HydrochlorideIneos Healthcare Limited · terminated · Chronic Kidney Failure · study chair
- Ph3NCT00841126 · Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum CarbonateIneos Healthcare Limited · terminated · Chronic Kidney Failure · study chair
- Ph3NCT00753896 · Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With MetforminAstraZeneca · completed · Type 2 Diabetes · study director
- Ph4NCT00729326 · Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00702143 · A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)Avid Radiopharmaceuticals · completed · Alzheimer's Disease, Mild Cognitive Impairment · study director
- Ph2NCT00701935 · Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With MetforminAstraZeneca · terminated · Diabetes Mellitus · study director
- Ph3NCT00676338 · Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)AstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00642616 · Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseMannkind Corporation · terminated · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease · study chair
- Ph3NCT00641056 · Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)AstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- N/ANCT00622323 · Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino PatientsAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph1NCT00612794 · A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes · study director
- Ph3NCT00603239 · Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and MetforminAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00577824 · Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)AstraZeneca · completed · Type 2 Diabetes · study director
- Ph3NCT00516048 · An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00516074 · A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00434954 · Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesAstraZeneca · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00082381 · Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminAstraZeneca · completed · Diabetes Mellitus, Type 2 · study director
- Ph3NCT00082407 · Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminAstraZeneca · completed · Diabetes Mellitus, Type 2 · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use DisorderU01DA055481 · NIDA · INTERVEXION THERAPEUTICS, LLC · PI W BROOKS GENTRY, Misty Ward Stevens · fiscal years 2021 to 2023Named on NCT05034874
- STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient TherapyU01DA045366 · NIDA · INTERVEXION THERAPEUTICS, LLC · PI W BROOKS GENTRY, Misty Ward Stevens · fiscal years 2017 to 2019Named on NCT05027451
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2008 to 2026Named on NCT04977024, NCT04639466
- Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTSU01DA053043 · NIDA · INTERVEXION THERAPEUTICS, LLC · PI W BROOKS GENTRY, Misty Ward Stevens · fiscal years 2020 to 2022Named on NCT04715230
- 18F-AV-45 PET Imaging of Amyloid in PD with Cognitive ImpairmentR43NS063607 · NINDS · AVID RADIOPHARMACEUTICALS, INC. · PI Daniel M. Skovronsky · fiscal years 2008 to 2009Named on NCT00857532
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.